Merck (MRK) Declares $0.48 Quarterly Dividend; 3.3% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Goldman Sachs Says Merck (MRK) 'Likely to be the Dominant Player in All of NSCLC'
May 23, 2018 9:26 AM EDTMerck (NYSE: MRK) announced that its phase 3 trial in 1L squamous NSCLC, KN-407 met its dual primary endpoint of OS and PFS based on an interim analysis conducted by the DMC. Goldman Sachs expects full data at ASCO and anticipated this update after... More
Congo begins giving experimental Ebola vaccine to medics
May 21, 2018 6:51 AM EDTBy Patient Ligodi
MBANDAKA, Democratic Republic of Congo (Reuters) - Congo began administering an experimental Ebola vaccine to medical staff in the northwestern city of Mbandaka on Monday to tackle an outbreak of the virus believed to have killed 26 people since early April.
The World Health Organization (WHO) hailed the vaccinations as a "paradigm shift" in how to fight the disease which killed more than 11,300 people in a West African epidemic between 2013 and 2016.
The WHO is sending over 7,540 doses of the vaccine to the central African country, 540 of which have been earmarked for Mbandaka, a city of... More
